Angeles A. Secord, MD, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.
Angeles A. Secord, MD, gynecologic oncologist, Duke Cancer Center, discusses the individual therapeutic preferences and treatment considerations for patients with platinum-sensitive ovarian cancer.
If a patient does not wish to undergo chemotherapy, it important to understand any specific concerns regarding toxicity, according to Secord. However, PARP inhibitors represent a feasible option for these patients Secord says. Trials such as the phase 3 GY004 trial (NCT02446600) and phase 3 SOLO-3 (NCT02282020) with olaparib (Lynparza), and the phase 3 ARIEL4 trial (NCT02855944) with rucaparib (Rubraca), have demonstrated that patients with BRCA1/2 mutations can achieve robust responses and disease control on these drugs, Secord explains.
Another consideration is the goal of therapy, in terms of avoiding toxicity and maximizing quality-of-life, Secord notes. Often, these goals are not the same for all patients, Secord continues. For example, although some patients may prefer oral therapy with a pill, others may prefer IV therapy. As such, these conversations with patients are crucial, Secord concludes.